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Background: Progressive supranuclear palsy and Parkinson’s disease have characteristic clinical and
neuropathologic profiles, but also share overlapping clinical features. This study aimed to analyze the gait of people
with progressive supranuclear palsy (n=19) and compare it with people with Parkinson’s disease (n=20) and healthy
older adults (n=20).
Methods: Gait was recorded at self-selected preferred, fast, very fast, slow and very slow speeds. Stride length was
normalized to leg length. Linear regression analyses were carried out between cadence and stride length. Other
gait variables were compared for each participant’s ‘walk’ which had stride length closest to 1.4.
Results: All groups showed a strong linear relationship between stride length and cadence with no difference
between groups (p>0.05). The intercept between cadence and stride length was lowest in the progressive
supranuclear palsy group and highest for older adults (p<0.001). The progressive supranuclear palsy group had
higher cadence than older adults (p>0.05), and greater step width and greater double support phase compared
with the other two groups (p<0.05).
Conclusions: The temporal-spatial gait characteristics of progressive supranuclear palsy and Parkinson’s disease are
largely similar, with similar disruption to scaling of stride length. The additional findings of increased step width and
double support percentage suggest increased severity of gait abnormality compared to Parkinson’s disease, despite
similar disease duration. The findings are consistent with the clinical features of greater instability and more rapid
disease progression in progressive supranuclear palsy compared to Parkinson’s disease and implicates the early
pathological involvement of brain regions involved in gait control.
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Progressive supranuclear palsy (PSP) [1] is the second
most common cause of neurodegenerative parkinsonism,
and causes progressive deterioration in motor and subcor-
tical cognitive function. The neuropathologic features of
PSP include marked midbrain atrophy and atrophy of the
pallidum, thalamus, subthalamic nucleus and frontal lobes
[2]. Clinically, PSP is a degenerative movement disorder* Correspondence: robert.iansek@monash.edu
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reproduction in any medium, provided the orwith a variable clinical presentation that includes vertical
gaze palsy, pseudobulbar palsy, axial rigidity, and cogni-
tive impairment. Patients typically have bradykinesia, the
appearance of a fixed stare and a soft, slurred, growly
voice [3]. Gait disturbance is recognized as one of the
core diagnostic criteria and may present as short, shuf-
fling steps, gait freezing, lurching unsteady gait or spon-
taneous falls, which may become the dominant features
[3,4]. Diagnosis can be difficult and often takes several
years due to the variability of presenting signs and symp-
toms and frequency of atypical presentations [3].
In the early stages, PSP can be difficult to distinguish
from PD as both patients develop hypomimia, shuffling
gait, freezing and bradykinesia [5]. The forward flexedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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PSP tend to be backwards [6]. Although gait changes are
an important clinical feature of PSP, it has not been sys-
tematically analyzed and compared to patients with PD.
Assessing the temporal-spatial characteristics of gait,
and comparing to people with PD and healthy older
adults (HOA), may help to identify distinguishing fea-
tures of PSP, permit further understanding of gait con-
trol pathways affected by PSP and in the longer term
contribute to the development of more effective,
disease-specific treatment options.
We sought to evaluate the temporal-spatial gait charac-
teristics in patients with PSP, and to compare with the gait
of people with hypokinetic gait due to PD and healthy
older adults. In this cross sectional study we aimed to
characterize gait using the stride length versus cadence
relationship (SLCrel) and parameters which relate to dy-
namic postural instability [7-10] and hypokinesia [11,12].
Methods
Nineteen people with clinically diagnosed probable PSP
[13] and 20 people with clinically diagnosed PD were
recruited from Movement Disorder Specialty Clinics. PD
patients were excluded if they experienced at least mod-
erate dyskinesias. Participants were tested on their usual
medications. The 20 HOA were recruited by conveni-
ence from our laboratory database and the local commu-
nity. All participants were required to be able to walk at
least 10m without physical assistance or use of a walking
aid, and achieved a Mini Mental State Examination score
of greater than 23/30 [14]. Potential participants were
excluded if they suffered from any other disease to a de-
gree that would likely effect their gait (for example,
lower limb or back pain during walking, hemiplegia from
stroke, peripheral neuropathy secondary to diabetes). All
participants gave their written informed consent and ap-
proval for the study was gained from the Southern
Health Research Ethics Committee.
The footstep patterns of participants were recorded
using a GAITRiteW walkway system (CIR Systems Inc.,
Havertown, PA) at self-selected speeds of very slow,
slow, preferred, fast and very fast. Gait variables deter-
mined from GAITRiteW have previously been shown to
be valid and highly reliable [15,16]. Three trials of each
speed were recorded with only the second and third
being used in the analysis. Trials at ‘preferred’ speed
were always recorded first to prevent subtle influence
from faster or slower walks. The remaining four speed
levels were performed in the order slow, very slow, fast
and finally very fast, or, fast, very fast, slow and finally
very slow. Participants were randomly allocated one of
the two orders. Close supervision was provided by
experienced clinicians, and a safety belt was worn by
most PD and PSP participants.Data screening and sometimes cropping of walks was
performed to ensure there were no data errors or anom-
alies in the walks such as stopping on the mat, festinat-
ing, or stepping off the side of the mat. Each walk used
in the analysis had a minimum of eight consecutive
steps. Speed normalized to leg length (nSp), stride length
normalized to leg length (nSL) and cadence, all recorded
at preferred speed, were compared. For comparisons of
preferred speed gait characteristics, the second and third
walks at self-selected preferred speed for each partici-
pant were averaged to produce one value per participant
before analysis of group data were carried out. Disease
severity was measured using PSP Rating Scale for PSP
participants (0 = no symptoms – 100) and Unified Par-
kinson’s disease Rating Scale – motor subsection
(UPDRS III) for PD participants (0 = no symptoms – 56).
Other gait variables of interest were speed dependent,
therefore the walk that resulted in nSL closest to 1.4 (the
mean nSL at preferred speed for the cohort, SD = 0.26)
was identified and used for further gait comparisons.
Similar stride length was used rather than similar speed
as stride length is a key determinant of speed, which in
turn is the combination of two variables. The variables
compared at comparable stride lengths were cadence,
double support percentage of gait cycle (DS%), step
width, stance time variability, and stride length variabil-
ity. Variability measures were calculated as the standard
deviation across all steps of the selected walk.
The minimum, maximum and range of both stride
length and cadence were determined for each individual
from the second and third walks at each of the five speed
conditions (ten walks). The nSL versus cadence relation-
ship (SLCrel) was examined using methods developed by
our group and previously described [12]. The slope,
intercept and R2 values were calculated from linear re-
gression using SPSS v18 (Chicago, IL). For this analysis,
walks with cadences of greater than 150 steps/min were
removed as we have previously found that after removing
walks with these very high cadences, almost all (95%)
SLCrels for healthy adults were strongly linear (R2 ≥
0.90) rather than quadratic [12]. The intercept was calcu-
lated at a cadence of 100steps/min to ensure it was
within the data range and more accurately reflected the
gain of the SLCrel than using an intercept at a cadence of
zero [12,17]. All comparisons between the groups for
each variable were carried out using one-way ANOVA
tests with Bonferroni post hoc analyses (SPSS v18,
Chicago, IL).
A regression line representing the SLCrel for each
group as a whole was also constructed using all
the individual data points from walks with cadences
< 150 steps/min. The group slopes and intercepts (again
at a cadence of 100steps/min) from these plots are also
reported.
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Demographic information is shown in Table 1. The HOA
participants were more likely to be female and weighed
less but there were no differences between the groups in
age or height. There was no significant difference be-
tween the PSP and PD groups in mean symptom dur-
ation, PSP 4.3 years (SD = 2.7) versus PD 6.6 years (SD =
5.8), or mean time since last levodopa medication for
those on medication, PSP (n = 9, 50% of sample) 3.0 h
(SD = 1.8) versus PD 2.2 h (SD = 1.5). The mean PSP
Rating Scale score for the PSP participants was 41.7/100
(SD = 17.2), while the mean UPDRS III score for the PD
participants was 14.4/56 (SD = 16.7).
At self-selected preferred speed, the PSP participants
walked slower and with shorter stride length than both
PD and HOA participants (Table 1). They had lower ca-
dence than HOA only. Figure 1 illustrates that the differ-
ent mean stride lengths account for more of the
differences in speed than cadence.
Walking with similar stride length, the PSP and PD
participants had significantly higher cadence than the
HOA group (Table 1). Significant group differences were
also found for DS% and step width, where the PSP group
differed from both PD and HOA groups, PSP having sig-
nificantly greater DS% and wider step width (Figure 1
and Table 1). There were no significant group differences
for stride length variability or stance time variability.
The SLCrel group data are presented in Table 2. All
SLCrels were examined and none were found to be
other than linear. Two PDs had very limited range of SL
which resulted in low R2 values (0.23 and 0.22). All
other participants had R2 values of > 0.83. The slopeTable 1 Demographic information
PSP (n = 19) PD
Age, yrs 69.1 (8.7) 68
Male, n(%) 16 (84)
Height, cm 170.6 (8.2) 171
Weight, kg 80.5 (13.5) 78
Symptom duration, yrs 4.3 (2.7) 6
Disease severity 41.7 (17.2) 14
Normalized speed 1.03 (0.27) 1.
Normalized stride length 1.2 (0.2) 1
Cadence (steps/min) 103.6 (9.3) 109
Cadence (steps/min)* 119.8 (15.4) 108
DS (%)* 31.1 (4.6) 27
Step width (cm)* 11.4 (4.2) 9
Stance time variability (sec)* 0.024 (0.009) 0.01
Stride length variability (cm)* 3.2 (1.7) 2
Mean (standard deviation, SD) for each group. Disease severity was measured using
Parkinson’s Disease Rating Scale – motor subsection (UPDRS III) for PD participants
and cadence for preferred speed walks. Mean (SD) of other gait parameters for the
* Determined from walk with normalized stride length closest to 1.4. PSP progressiv
double support percentage of gait cycle, n/s not statistically significant.and intercept values of these two outlying PDs were
excluded from the analysis. Differences between the
groups were found for SLCrel intercept which was low-
est for PSP and highest for HOA, minimum and max-
imum stride lengths, which were both lowest for PSP
and highest for HOA, and maximum and range of ca-
dence, which were both only different between PSP and
HOA, with PSP having lower maximum cadence and
smaller cadence range than HOA. The SLCrel plots for
all data points in each group are shown in Figure 2.
Discussion
This study provides temporal-spatial gait data for people
with PSP and compares their gait with PD and HOA.
Preferred speed walks showed decreased nSL to be the
main contributor to slowed walking speed in both PD
and PSP. PSP also had lower cadence than ‘normal’ at
preferred speed. People with PSP had reduced nSL for
their cadences across all the self-selected speeds (reduced
intercept) indicating an alteration in the gain of the nor-
mal stride length - cadence relationship.
Comparison of ‘walks’ at similar stride length showed
that people with PSP have significantly higher cadences
for the stride length than HOA and more ‘abnormal’ DS
% and step width than PD. The significantly increased
DS% and step width may be manifestations of unsteadi-
ness or compensations to enhance postural stability [8].
Falls are a cardinal feature of PSP and the occurrence of
falls has been linked to the presence of gaze problems,
axial rigidity, cognitive decline [4]. Increased DS% and
step width may be an indication that dynamic instability
is also a contributing factor to fall frequency in PSP.(n = 20) HOA (n = 20)
.3 (7.9) 71.8 (4.1) n/s
16 (80) 7 (35) P = 0.001
.8 (8.0) 166.6 (6.3) n/s
.3 (10.2) 68.4 (11.5) F2,56 = 5.9, P = 0.01
.6 (5.8) - n/s
.4 (16.7) - -
28 (0.22) 1.54 (0.16) F2,56 = 25.8, P < 0.001
.4 (0.2) 1.6 (0.1) F2,56 = 25.6, P < 0.001
.7 (6.9) 113.4 (7.0) F2,56 = 7.9, P = 0.001
.9 (18.9) 92.7 (9.5) F2,56 = 15.9, P < 0.001
.9 (3.0) 25.6 (2.7) F2,56 = 12.2, P < 0.001
.0 (2.9) 8.5 (2.9) F2,56 = 4.0, P = 0.02
8 (0.008) 0.025 (0.013) n/s
.4 (1.2) 2.8 (1.6) n/s
PSP Rating Scale for PSP participants (0=no symptoms – 100) and Unified
(0=no symptoms – 56). Mean (SD) normalized speed, normalized stride length
walk with normalized stride length closest to 1.4.
e supranuclear palsy, PD Parkinson’s disease, HOA healthy older adult, DS



































































Figure 1 Comparison of gait between groups. Mean ± 1SD for each group for cadence and normalized stride length at preferred speed, and
double support % of gait cycle and step width at similar stride lengths. *denotes significant difference between groups.
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PD group when compared with HOA, the finding may
be a result of greater overall severity of gait abnormality,
despite no difference in disease duration, among the PSP
group than for PD, rather than an additional gait abnor-
mality. This is consistent with the clinical finding of
more rapid disease progression for people with PSP.
There are features of PSP that are likely to contribute to
gait abnormalities. Motor causes include weakness and
spasticity, which along with bradykinesia is thought to ex-
plain the ‘lurching’ style gait [3]. Axial (more so than ap-
pendicular) rigidity and dystonia are often present. The









PSP 0.011 (0.004) 1.14 (0.20) 0.92 (0.08) 0.9 (0.3)
PD (n=18) 0.011 (0.004) 1.35 (0.22) 0.94 (0.06) 1.1 (0.2)
HOA 0.011 (0.005) 1.48 (0.07) 0.95 (0.04) 1.3 (0.1)
P = 0.75 F2,56 = 17.7,
P < 0.001
P = 0.15 F2,56 = 15.1,
P < 0.001
Mean (SD) for each group for the measures taken from ten walks (two each at self-
length – cadence relationship (SLCrel) measures excluded walks with cadence >150
SLCrel stride length versus cadence relationship, nSL normalized stride length, cad=
healthy older adult.convergence difficulties, reduced blinking and involuntary
eyelid closing, may also lead to gait alterations as well as
directly contributing to fall frequency [18] [3]. Finally,
many of the cognitive problems that are features of PSP
may contribute to gait instability, including apathy and
decline of executive function, reduced processing speed,
impaired attention, and diminished working memory.
Callisaya et al. [19] found that the speed of the walk
explained most of the variation in the temporal variabil-
ity found among older people. This, they presume, is be-
cause walking at slower speeds disrupts the temporal
automaticity of gait. In this study, we controlled for










1.4 (0.3) 0.57 (0.21) 74.9 (9.7) 128.9 (13.5) 54.1 (18.2)
1.7 (0.2) 0.55 (0.22) 82.7 (11.6) 137.8 (12.3) 55.1 (15.1)
1.9 (0.2) 0.68 (0.17) 78.1 (14.0) 147.8 (12.7) 69.6 (22.1)
F2,56 = 23.4,
P < 0.001




selected very slow, slow, preferred, fast and very fast speeds). Note the stride
steps/min and two outlying PD participants’ data was excluded












[R2 0.54, Slope 0.012, Intercept 1.14]
Healthy older adults
[R2 0.76, Slope 0.010, Intercept 1.50]
PD 
[R2 0.34, Slope 0.009, Intercept 1.33]
Figure 2 Stride length versus cadence. The normalized stride length versus cadence data points and regression lines for all the walks up to
cadence = 150steps/min for all participants in each group.
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for all the HOA, but was a fast or very fast walk for
most (84%) of the PSP. All participants may have been
influenced by the effect of non-preferred speed on vari-
ability, however stance time variability for all groups in
this study were comparable to that reported for older
adults, mean 0.02s (SD 0.01) [19].
This study showed that while the stride length versus
cadence relationship was intact in our PSP participants,
it had a lower intercept, that is, a smaller stride length
was associated with a higher cadence. This was also
characteristic of the PD group in this and previous stud-
ies [11], although the lower intercept in our PSP group
was more severe. This suggests that people with PSP
share the defective scaling of stride length that underlies
gait disturbance in PD, but to a more severe extent.
These findings are consistent with the concept of a mis-
match in stride length selection associated with basal
ganglia malfunction in both disease states. Given the
upper brain stem involvement in PSP we might have
expected some additional disturbance of cadence control
[20]. While the PSP group had lower cadence at pre-
ferred speed and higher cadence when walks with similar
stride lengths were compared, no disruption to the link-
age between stride length and cadence manifest in the
SLCrel. This may be expected to break down with pro-
gressive involvement of the lower brain stem, and may
be present in the PSP patients who did not satisfy inclu-
sion criteria for the present study.
The findings from this study indicate that some treat-
ment modalities that are successful in improving func-
tion for people with PD, such as the use of cueing when
walking to maintain stride length, may also be appropri-
ate for people with PSP. However, the instability-related
gait abnormalities found in this PSP group support theinclusion of additional treatment techniques to optimize
their gait and maintain independent functioning for as
long as possible.
The study findings need to be considered in the con-
text of several methodological limitations. There were
differences in the groups which may have an impact on
the data and the conclusions that can be drawn. While
disease duration was similar, it was not possible to dir-
ectly compare disease severity between the two patient
groups as two different scales were used. Differences in
disease severity may explain some of the differences in
gait between the patient groups.
The difficulty in recruiting participants with PSP who
meet the inclusion/exclusion criteria for this study has
resulted in low participant numbers. The testing was car-
ried out without withholding of levodopa medication. All
PD participants and half of the PSP participants were
prescribed levodopa medication. Levodopa medication is
known to normalize stride length and the stride length
versus cadence relationship intercept for people with PD
[11]. It is not known whether it achieves a similar effect
on gait in PSP and some of the gait abnormalities may be
underrated particularly among the PD group. While this
may be seen as a limitation, the data reflects the presen-
tation of gait abnormalities seen in clinical settings.
Given that gait within patients with advanced PD fluctu-
ates extensively and often does not follow a predictable
pattern related to medication timing [21], and the clinical
presentation among our small cohort of PSP patients was
considerably heterogeneous, we were not able to carry
out a comparison of gait between the PSP patients pre-
scribed versus not prescribed levodopa medication. How-
ever, we recommend such a study for future research.
That there were more females in the HOA group may
have impacted on the results. Gender differences are
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length where females have lower speed and shorter
stride length than males [22]. That we never-the-less
found significant differences between the groups in these
two variables indicates that the group gender differences
are unlikely to have impacted on our conclusions.
Weight was previously not found to be associated with
similar gait variables in a population based study of older
people [19].
Conclusions
These findings indicate that PSP pathology affects gait
control pathways that are also affected in PD. Gait
changes associated with defective scaling of stride length
and postural instability were more marked in PSP than
those with PD despite similar disease duration between
the groups. This may be a manifestation of more rapid
progression of the disease or damage to additional path-
ways in PSP.
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